Cargando…
Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma
BACKGROUND: It is widely accepted that maximal extrathyroidal extension (ETE) plays a vital role in the prognosis of papillary thyroid carcinoma (PTC). However, there is no consensus among researchers about the meaning of minimal ETE (mETE) in PTC. Herein, we conducted a systematic review and meta-a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207600/ https://www.ncbi.nlm.nih.gov/pubmed/28033304 http://dx.doi.org/10.1097/MD.0000000000005794 |
_version_ | 1782490394956660736 |
---|---|
author | Yin, De-Tao Yu, Kun Lu, Run-Qing Li, Xianghua Xu, Jianhui Lei, Mengyuan |
author_facet | Yin, De-Tao Yu, Kun Lu, Run-Qing Li, Xianghua Xu, Jianhui Lei, Mengyuan |
author_sort | Yin, De-Tao |
collection | PubMed |
description | BACKGROUND: It is widely accepted that maximal extrathyroidal extension (ETE) plays a vital role in the prognosis of papillary thyroid carcinoma (PTC). However, there is no consensus among researchers about the meaning of minimal ETE (mETE) in PTC. Herein, we conducted a systematic review and meta-analysis to examine the role of mETE in the prognosis of PTC. METHODS: We searched PubMed, EMBASE, and Cochrane search trials databases in English to identify studies comparing data on disease recurrence in PTC patients with mETE and those with no ETE. To summarize the data related to mETE status, risk ratios and hazard ratios adjusted for potential confounders were used to assess the number of recurrence and time-dependent risks related to mETE status, respectively. RESULTS: According to the inclusion criteria, a total of 7951 patients from 9 studies were included. The recurrence rate in patients with mETE is significantly higher when compared with those with no ETE (risk ratio = 1.70, 95% confidence interval: 1.26–2.28, I(2) = 56%). According to the data summarized with hazard ratios, PTC patients with mETE showed a significantly increased risk of disease recurrence. CONCLUSION: mETE is a risk factor for poor prognosis in patients with PTC. Our innovative classification of ETE has its value in assessing the prognosis of PTC. |
format | Online Article Text |
id | pubmed-5207600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-52076002017-01-09 Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma Yin, De-Tao Yu, Kun Lu, Run-Qing Li, Xianghua Xu, Jianhui Lei, Mengyuan Medicine (Baltimore) 4300 BACKGROUND: It is widely accepted that maximal extrathyroidal extension (ETE) plays a vital role in the prognosis of papillary thyroid carcinoma (PTC). However, there is no consensus among researchers about the meaning of minimal ETE (mETE) in PTC. Herein, we conducted a systematic review and meta-analysis to examine the role of mETE in the prognosis of PTC. METHODS: We searched PubMed, EMBASE, and Cochrane search trials databases in English to identify studies comparing data on disease recurrence in PTC patients with mETE and those with no ETE. To summarize the data related to mETE status, risk ratios and hazard ratios adjusted for potential confounders were used to assess the number of recurrence and time-dependent risks related to mETE status, respectively. RESULTS: According to the inclusion criteria, a total of 7951 patients from 9 studies were included. The recurrence rate in patients with mETE is significantly higher when compared with those with no ETE (risk ratio = 1.70, 95% confidence interval: 1.26–2.28, I(2) = 56%). According to the data summarized with hazard ratios, PTC patients with mETE showed a significantly increased risk of disease recurrence. CONCLUSION: mETE is a risk factor for poor prognosis in patients with PTC. Our innovative classification of ETE has its value in assessing the prognosis of PTC. Wolters Kluwer Health 2016-12-30 /pmc/articles/PMC5207600/ /pubmed/28033304 http://dx.doi.org/10.1097/MD.0000000000005794 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 4300 Yin, De-Tao Yu, Kun Lu, Run-Qing Li, Xianghua Xu, Jianhui Lei, Mengyuan Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title | Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title_full | Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title_fullStr | Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title_full_unstemmed | Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title_short | Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
title_sort | prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma |
topic | 4300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207600/ https://www.ncbi.nlm.nih.gov/pubmed/28033304 http://dx.doi.org/10.1097/MD.0000000000005794 |
work_keys_str_mv | AT yindetao prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma AT yukun prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma AT lurunqing prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma AT lixianghua prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma AT xujianhui prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma AT leimengyuan prognosticimpactofminimalextrathyroidalextensioninpapillarythyroidcarcinoma |